Gepirone (Exxua): New Antidepressant FDA Approved for MDD
On Sep 28, 2023: Fabre-Kramer Pharmaceuticals Announcesd the FDA Approval of EXXUA™, the Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder…
Tag: MDD
Severe Melancholic Depression: How to Manage?
Melancholic features in major depressive disorder are characterized by: ONE of the following present during the most severe period of the current episode: Loss of…
How to use Transdermal Selegiline for MDD?
Monoamine Oxidase Inhibitors (MAOIs) have not only shown efficacy with treatment resistant depression, but are also found efficacious for the treatment of depression in the…
Trazodone Once-A-Day (TzOAD) for MDD?
Trazodone belongs to a class of antidepressant medications called serotonin antagonists and reuptake inhibitors (SARIs). Traozodone is used more for insomnia treatment compared to MDD…
Persistent Complex Bereavement Disorder & Prolonged Grief Disorder
As medical professionals, we are often tasked with helping our patients navigate the complexities of grief and loss. Losing a loved one is a deeply painful…
MDD Augmentation: Low Dose Naltrexone
We finish our lecture series “10 Augmentation Strategies for MDD” with our tenth (and last) lecture on the role of Low Dose Naltrexone as an…
MDD Augmentation: S-Adenosyl Methionine (SAMe)
We continue our lecture series “10 Augmentation Strategies for MDD” with our ninth lecture on the role of SAMe as an augmentation for major depressive…
MDD Augmentation: Pramipexole
We continue our lecture series “10 Augmentation Strategies for MDD” with our eighth lecture on the role of Pramipexole as an augmentation for major depressive…
MDD Augmentation: Stimulants
We continue our lecture series “10 Augmentation Strategies for MDD” with our sixth lecture on the role of Stimulants as an augmentation for major depressive…
MDD Augmentation: Lamotrigine
We continue our lecture series “10 Augmentation Strategies for MDD” with our fifth lecture on the role of Lamotrigine as an augmentation for major depressive…
MDD Augmentation: L-MethylFolate
We continue our lecture series “10 Augmentation Strategies for MDD” with our fourth lecture on the role of L-MethylFolate as an augmentation for major depressive…
MDD Augmentation: Thyroid Hormone
We continue our lecture series “10 Augmentation Strategies for MDD” with our third lecture on the role of thyroid hormine as an augmentation for major…
MDD Augmentation: Lithium
We continue our lecture series “10 Augmentation Strategies for MDD” with our second lecture on the role of lithium as an augmentation for major depressive…
MDD Augmentation: Atypical Antipsychotics
It is known that close to 50% of patients with major depressive episodes may not achieve remission after the trials of first-line antidepressants, and only…
Cariprazine: New FDA Indication for MDD Augmentation
On Dec 16, 2022: AbbVie announced that FDA has approved Cariprazine as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in…
Augmentation Strategies for Major Depressive Disorder
PSYCHIATRY EDUCATION FORUM ACADEMY’S LECTURE SERIES: MAJOR DEPRESSIVE DISORDER: 10 AUGMENTATION STRATEGIES Introduction Psychiatry Education Forum Academy continues to provide high-quality, evidence-based & practice-oriented discussions…
Single-Dose Psilocybin for a Treatment-Resistant Depression?
Psychiatry Education Forum Academy is excited to announce the release of Academy’s 19th Journal Club discussion today: This article was published in the NEJM on…
Managing Treatment Resistant Depression with Atypical Features
Depression with atypical features is defined as significant mood reactivity combined with two of the following clinical features: Hyperphagia Hypersomnia Leaden paralysis Pathological rejection sensitivity…
Can St. John’s Wort help with Depression?
Psychiatry Education Forum Academy is excited to announce our next presentation’s release date for Sep 10, 2022: WATCH INTRODUCTION VIDEO https://youtu.be/Q01KwQTdTqM There are many plant-based…
Auvelity: New Oral Fast Acting FDA Approved Antidepressant
On Aug 19, 2022 Axsome Therapeutics announced the FDA Approval of Auvelity, as the first and Only Oral NMDA Receptor Antagonist for the treatment of…
Omega-3 Fatty Acids for Depression?
Recently Omega-3 polyunsaturated fatty acids, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) have drawn the clinical attention for the treatment of major depressive disorder. The…
How Long to Continue Antidepressants for MDD Treatment?
Once you have initiated antidepressants for MDD (Major Depressive Disorder) treatment and the patient has achieved remission, how long will you continue this current antidepressant…
Treatment-Resistant MDD: Modafinil Augmentation
Partial response, no response, or residual symptoms following antidepressant therapy is common in clinical psychiatry. Hence, it is of clinical importance to have knowledge of…
Journal Club #2: Omega-3 Fatty Acids for MDD Treatment (ISNPR Practice Guidelines)
Today we posted the following second journal club in PEFA Journal Club’s discussion series: Journal Club #2: International Society for Nutritional Psychiatry Research Practice Guidelines…
Journal Club #1: Update on Nonpsychotic Unipolar Depression Management
We begin PEFA Journal Club’s updated schedule with our first journal club discussion today: Journal Club #1: The Psychopharmacology Algorithm Project at the Harvard South…
Medications vs Psychotherapy for MDD: Comparing 5 Major Guidelines
How do you decide between psychotherapy versus medications for the treatment of major depressive disorder? Depression severity is one of the criteria used to make…